<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018523</url>
  </required_header>
  <id_info>
    <org_study_id>H-32774</org_study_id>
    <nct_id>NCT02018523</nct_id>
  </id_info>
  <brief_title>Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer</brief_title>
  <official_title>A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of maintenance therapy
      with daily low dose lenalidomide in patients with stage IIIB/IV non-small cell lung cancer
      (NSCLC) after first line chemotherapy. Investigators expect this treatment approach will
      delay disease progression by boosting the patient's anti-tumor immune response. Investigators
      hypothesize that 10 mg/day of lenalidomide can be administered safely as maintenance therapy
      and improve progression free survival time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with stage IIIB/IV non-small cell lung cancer, who did not progress after first
      line chemotherapy, lenalidomide 10mg/day orally will be administered as maintenance therapy
      until disease progression or death.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study did not enroll enough subjects to make a statistically sound conclusion.
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 6 months from the date of registration</time_frame>
    <description>Progression free survival is defined as the duration of time from the date starting lenalidomide to the date of documented radiographic progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From date of registration to end of study, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating immune cells</measure>
    <time_frame>Change from baseline at 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating immune cells</measure>
    <time_frame>Change from baseline at 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating immune cells</measure>
    <time_frame>Change from baseline at 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating immune cells</measure>
    <time_frame>Change from baseline at 13, 17, 21 and 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating immune cells</measure>
    <time_frame>Change from baseline to 6 months, 9 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating immune cells</measure>
    <time_frame>Change from baseline to 1.5, 2, 2.5 and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral lenalidomide 10 mg daily until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>lenalidomide 10mg/day orally until disease progression</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed stage IIIB or stage IV
             NSCLC with measurable disease at initial presentation prior to chemotherapy. See
             Section 8.4.1 for measurable disease parameters.

          -  Patients must have had a complete response (CR), partial response (PR) or stable
             disease (SD) after 4-6 cycles of first-line chemotherapy. Tumor response will be
             assessed by RECIST criteria version 1.1.

          -  Patients must have fully recovered from the acute toxic effects of all prior
             chemotherapy, or radiotherapy before entering this study.

               1. Myelosuppressive chemotherapy: At least 21 days elapsed from end of treatment
                  before registration (42 days if prior nitrosourea).

               2. Hematopoietic growth factors: At least 7 days since the completion of therapy
                  with a growth factor.

               3. Other: For agents that have known adverse events occurring beyond 7 days after
                  administration, this period must be extended beyond the time during which adverse
                  events are known to occur.

               4. XRT: &gt; or = to 2 weeks for local palliative XRT (small port); 3 months must have
                  elapsed if 50% radiation of pelvis; 6 weeks must have elapsed if other
                  substantial bone marrow radiation.

          -  Patients must be &gt; or = 18 years of age.

          -  ECOG performance status &lt; or = to 1 (Karnofsky &gt; 70%).

          -  Organ Functions: Patients must have normal organ and marrow function as defined below
             within 28 days of registration:

               1. Leukocytes &gt; or = 3,000/uL

               2. Absolute neutrophil count &gt; or = 1,500/uL

               3. Hemoglobin &gt; or = 8 g/dL

               4. Platelets &gt; or = 100,000/uL

               5. Total bilirubin 1.5X institutional upper limit of normal (ULN)

               6. AST (SGOT) and ALT (SGPT) 1.5X institutional ULN

               7. Creatinine clearance &gt; or = 60 mL/min/1.73 m2 for patients with creatinine levels
                  &gt; institutional normal

          -  All study participants must be willing and agree to be registered into the mandatory
             REVLIMID REMS program, and be willing and able to comply with the requirements of
             REVLIMID REM. REVLIMID REMS registration does not need to be complete to determine
             study eligibility.

          -  Females of childbearing potential (FCBP)* must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days before
             registration. Treating investigator must affirm intention to perform another serum or
             urine UPT 24 hours before initiating lenalidomide treatment.

             *FCBP: A female of childbearing potential (FCBP) is a sexually mature female who: 1)
             has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
             naturally postmenopausal (amenorrhea following cancer therapy does not rule out
             childbearing potential) for at least 24 consecutive months (i.e., has had menses at
             any time in the preceding 24 consecutive months).

          -  All patients must be counseled about pregnancy precautions, risks of fetal exposure
             and other risks. The counseling must be done before the initiation of the study and
             every 28 days before the study drug is dispensed to the subject. FCBP must either
             commit to continued abstinence from heterosexual intercourse or begin TWO acceptable
             methods of birth control, one highly effective method and one additional effective
             method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP
             must also agree to ongoing pregnancy testing. Men must agree to use a latex condom
             during sexual contact with a FCBP even if they have had a successful vasectomy. See
             Appendix D: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth
             Control Methods.

          -  Able to take aspirin (81 mg) daily as prophylactic anticoagulation (Patients
             intolerant to ASA may use warfarin or low molecular weight heparin).

          -  Able to understand and willing to sign a written informed consent document.

          -  Life expectancy &gt; or = 12 weeks

        Exclusion Criteria

          -  Concomitant Medications:

               1. Patients may not be receiving any other anti-cancer therapy.

               2. Patients may not be receiving any other investigational agents.

               3. Patients may not be receiving systemic steroids or other immunosuppressive drugs;
                  however, steroid containing inhaler may be allowed after discussing with the
                  Principal Investigator. Duration of 5 half-lives must have elapsed before the
                  study registration if the patient was on systemic steroids or other
                  immunosuppressive drugs.

          -  Patients with untreated brain metastasis, or with treated brain metastasis but
             requiring steroids.

          -  Patients with known EGFR mutation or EML-ALK fusion gene and with stage IV disease.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to lenalidomide or thalidomide.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, myocardial infarction within the last
             6 months, unstable angina pectoris, cardiac arrhythmia, autoimmune disease or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Pregnant or breastfeeding women are excluded from this study because lenalidomide has
             the potential for teratogenic or abortifacient effects. Because there is an unknown
             but potential risk for adverse events in nursing infants secondary to treatment of the
             mother with lenalidomide, breastfeeding should be discontinued if the mother is
             treated with lenalidomide.

          -  Known sera-positive for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are
             seropositive because of hepatitis B virus vaccine are eligible.

          -  Any other clinically significant medical condition and/or organ dysfunction that will
             interfere with the administration of the therapy according to this protocol or which,
             in the views of investigator, preclude combination chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.</citation>
    <PMID>11784875</PMID>
  </reference>
  <reference>
    <citation>Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.</citation>
    <PMID>20493771</PMID>
  </reference>
  <reference>
    <citation>Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Aug 10;31(23):2895-902. doi: 10.1200/JCO.2012.47.1102. Epub 2013 Jul 8.</citation>
    <PMID>23835707</PMID>
  </reference>
  <reference>
    <citation>Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18.</citation>
    <PMID>19767093</PMID>
  </reference>
  <reference>
    <citation>Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008 May 30;133(5):775-87. doi: 10.1016/j.cell.2008.05.009. Review.</citation>
    <PMID>18510923</PMID>
  </reference>
  <reference>
    <citation>Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008 Aug 15;14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133.</citation>
    <PMID>18698040</PMID>
  </reference>
  <reference>
    <citation>Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008 Sep 15;113(6):1387-95. doi: 10.1002/cncr.23712.</citation>
    <PMID>18671239</PMID>
  </reference>
  <reference>
    <citation>Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006 Dec 15;107(12):2866-72.</citation>
    <PMID>17099880</PMID>
  </reference>
  <reference>
    <citation>Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010 May;5(5):585-90. doi: 10.1097/JTO.0b013e3181d60fd7.</citation>
    <PMID>20234320</PMID>
  </reference>
  <reference>
    <citation>Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012 Aug;77(2):306-11. doi: 10.1016/j.lungcan.2012.04.011. Epub 2012 May 17.</citation>
    <PMID>22608141</PMID>
  </reference>
  <reference>
    <citation>Karagöz B, Bilgi O, Gümüs M, Erikçi AA, Sayan O, Türken O, Kandemir EG, Oztürk A, Yaylaci M. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol. 2010 Mar;27(1):29-33. doi: 10.1007/s12032-008-9165-9. Epub 2009 Jan 16.</citation>
    <PMID>19148592</PMID>
  </reference>
  <reference>
    <citation>Elias D, Lasser PH, Desruennes E, Mankarios H, Jiang Y. Surgical approach to segment I for malignant tumors of the liver. Surg Gynecol Obstet. 1992 Jul;175(1):17-24.</citation>
    <PMID>1621195</PMID>
  </reference>
  <reference>
    <citation>Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005 Nov;14(5):1269-73.</citation>
    <PMID>16211295</PMID>
  </reference>
  <reference>
    <citation>Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002 May 1;168(9):4272-6.</citation>
    <PMID>11970966</PMID>
  </reference>
  <reference>
    <citation>LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 1;103(5):1787-90. Epub 2003 Sep 25.</citation>
    <PMID>14512311</PMID>
  </reference>
  <reference>
    <citation>Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28.</citation>
    <PMID>16569772</PMID>
  </reference>
  <reference>
    <citation>Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009 Jul;58(7):1033-45. doi: 10.1007/s00262-008-0620-4. Epub 2008 Nov 14.</citation>
    <PMID>19009291</PMID>
  </reference>
  <reference>
    <citation>Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4.</citation>
    <PMID>18805433</PMID>
  </reference>
  <reference>
    <citation>Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005 Jan;69(1-2):56-63.</citation>
    <PMID>15797261</PMID>
  </reference>
  <reference>
    <citation>Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010 Jan 1;116(1):146-54. doi: 10.1002/cncr.24686.</citation>
    <PMID>19862820</PMID>
  </reference>
  <reference>
    <citation>Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May;2(5):445-9.</citation>
    <PMID>17473661</PMID>
  </reference>
  <reference>
    <citation>Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol. 2009 Jun;49(6):650-60. doi: 10.1177/0091270009335001.</citation>
    <PMID>19451403</PMID>
  </reference>
  <reference>
    <citation>Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004 Mar 8;90(5):955-61.</citation>
    <PMID>14997189</PMID>
  </reference>
  <reference>
    <citation>Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs. 2009 Oct;27(5):453-60. doi: 10.1007/s10637-008-9200-x. Epub 2008 Nov 15.</citation>
    <PMID>19011760</PMID>
  </reference>
  <reference>
    <citation>Kalmadi S, Davis M, Dowlati A, O'Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T. Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs. 2007 Jun;25(3):211-6. Epub 2006 Nov 11.</citation>
    <PMID>17103043</PMID>
  </reference>
  <reference>
    <citation>Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.</citation>
    <PMID>22571202</PMID>
  </reference>
  <reference>
    <citation>McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.</citation>
    <PMID>22571201</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Stage 3B/4</keyword>
  <keyword>Maintenance Therapy</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

